Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)

被引：0

作者：

Giagounidis, A. ^{[1
]}

Ades, L. ^{[2
]}

Watts, J. ^{[3
]}

Radinoff, A. ^{[4
]}

Arnan Sangerman, M. ^{[5
]}

Cerrano, M. ^{[6
]}

Font Lopez, P. ^{[7
]}

Zeidner, J. ^{[8
]}

Diez Campelo, M. ^{[9
,10
]}

Graux, C. ^{[11
]}

Liesveld, J. ^{[12
]}

Selleslag, D. ^{[13
]}

Tzvetkov, N. ^{[14
]}

Fram, R. J. ^{[15
]}

Zhao, D. ^{[15
]}

Bell, J. ^{[15
]}

Friedlander, S. ^{[15
]}

Faller, D. V. ^{[15
]}

Sekeres, M. A. ^{[16
]}

机构：

[1] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany

[2] Hop St Louis, Paris, France

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Univ Hosp Sveti Ivan Rislki, Sofia, Bulgaria

[5] Inst Catala Oncol Inst Invest Biomed Bellvitge ID, Barcelona, Spain

[6] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain

[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain

[10] Ctr Canc Res IBMCC USAL CSIC, Salamanca, Spain

[11] Catholic Univ Louvain, Ctr Hosp Univ, Namur, Belgium

[12] Univ Rochester, James P Wilmot Canc Inst, Rochester, NY 14627 USA

[13] AZ Sint Jan Brugge Oostende, Brugge, Belgium

[14] MHAT Dr Georgi Stranski, Clin Haematol, Pleven, Bulgaria

[15] Millennium Pharmaceut Inc, Cambridge, MA USA

[16] Cleveland Clin, Cleveland, OH 44106 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

653

引用

页码：171 / 171

页数：1

共 50 条

[1] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
Watts, Justin
Ades, Lionel
Radinoff, Atanas
Arnan Sangerman, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
[2] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Ades, Lionel
Watts, Justin M.
Radinoff, Atanas
Arnan, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua F.
Diez-Campelo, Maria
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Faller, Douglas, V
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia: a phase 2 randomized study
Ades, Lionel
Watts, Justin
Radinoff, Atanas
Arnan Sangerman, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua F.
Diez Campelo, Maria
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Sekeres, Mikkael A.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 6 - 7
[4] PHASE 2 STUDY OF PEVONEDISTAT plus AZACITIDINE vs AZACITIDINE IN PATIENTS WITH HIGH-RISK MYELODISPLASIC SYNDROME (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) OR ACUTE MYELOID LEUKEMIA (AML) <30% BLAST (NCT02610777)
Diez, Campelo Maria
Ades, Lionel
Watts, Justin
Radinoff, Atanas
Arnan, Sangerman Montserrat
Cerrano, Marco
Font, Lopez Patricia
Zeidner, Joshua
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Sekeres, Mikkael A.
HAEMATOLOGICA, 2020, 105 : 71 - 72
[5] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Sekeres, Mikkael A.
Watts, Justin
Radinoff, Atanas
Sangerman, Montserrat Arnan
Cerrano, Marco
Lopez, Patricia Font
Zeidner, Joshua F.
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Ades, Lionel
LEUKEMIA, 2021, 35 (07) : 2119 - 2124
[6] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres
Justin Watts
Atanas Radinoff
Montserrat Arnan Sangerman
Marco Cerrano
Patricia Font Lopez
Joshua F. Zeidner
Maria Diez Campelo
Carlos Graux
Jane Liesveld
Dominik Selleslag
Nikolay Tzvetkov
Robert J. Fram
Dan Zhao
Jill Bell
Sharon Friedlander
Douglas V. Faller
Lionel Adès
Leukemia, 2021, 35 : 2119 - 2124
[7] Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres
Justin Watts
Atanas Radinoff
Montserrat Arnan Sangerman
Marco Cerrano
Patricia Font Lopez
Joshua F. Zeidner
Maria Diez Campelo
Carlos Graux
Jane Liesveld
Dominik Selleslag
Nikolay Tzvetkov
Robert J. Fram
Dan Zhao
Jill Bell
Sharon Friedlander
Douglas V. Faller
Lionel Adès
Leukemia, 2021, 35 : 3637 - 3637
[8] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
Sekeres, Mikkael A.
Fram, Robert J.
Hua, Zhaowei
Ades, Lionel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Ades, Lionel
Girshova, Larisa
Doronin, Vadim A.
Diez-Campelo, Maria
Valcarcel, David
Kambhampati, Suman
Viniou, Nora-Athina
Woszczyk, Dariusz
De Paz Arias, Raquel
Symeonidis, Argiris
Anagnostopoulos, Achilles
Ciliao Munhoz, Eduardo
Platzbecker, Uwe
Santini, Valeria
Fram, Robert J.
Yuan, Ying
Friedlander, Sharon
Faller, Douglas, V
Sekeres, Mikkael A.
BLOOD ADVANCES, 2022, 6 (17) : 5132 - 5145
[10] Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)
Watts, Justin
Sekeres, Mikkael
Radinoff, Atanas
Arnan, Montserrat
Cerrano, Marco
Lopez, Patricia Font
Zeidner, Joshua
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolai
Fram, Robert
Zhao, Dan
Friedlander, Sharon
Galinsky, Kevin
Faller, Douglas
Ades, Lionel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S347 - S348

← 1 2 3 4 5 →